Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 04 2019
Historique:
pubmed: 21 3 2019
medline: 6 2 2020
entrez: 21 3 2019
Statut: ppublish

Résumé

Cardiovascular disease (CVD) is a leading cause of death among patients with end-stage renal disease (ESRD). Young adult (ages 22-29 years) have risks for ESRD-associated CVD that may vary from other ages. To test the hypothesis that young adult-onset ESRD is associated with higher cardiovascular (CV) hospitalizations and mortality with different characteristics than childhood-onset disease. This population-based cohort study used the US Renal Data System to categorize patients who initiated ESRD care between 2003 and 2013 by age at ESRD onset (1-11, 12-21, and 22-29 years). Cardiovascular hospitalizations were identified via International Classification of Diseases, Ninth Revision discharge codes and CV mortality from the Centers for Medicare & Medicaid ESRD Death Notification Form. Patients were censored at death from non-CVD events, loss to follow-up, recovery, or survival to December 31, 2014. Adjusted proportional hazard models (95% CI) were fit to determine risk of CV hospitalization and mortality by age group. Data analysis occurred from May 2016 and December 2017. Onset of ESRD. Cardiovascular mortality and hospitalization. A total of 33 156 patients aged 1 to 29 years were included in the study population. Young adults (aged 22-29 years) had a 1-year CV hospitalization rate of 138 (95% CI, 121-159) per 1000 patient-years. Young adults had a higher risk for CV hospitalization than children (aged 1-11 years; hazard ratio [HR], 0.41 [95% CI, 0.26-0.64]) and adolescents (aged 12-21 years; HR, 0.86 [95% CI, 0.77-0.97]). Of 4038 deaths in young adults, 1577 (39.1%) were owing to CVD. Five-year cumulative incidence of mortality in this group (7.3%) was higher than in younger patients (adolescents, 4.0%; children, 1.7%). Adjusted HRs for CV mortality were higher for young adults with all causes of ESRD than children (cystic, hereditary, and congenital conditions: HR, 0.22 [95% CI, 0.11-0.46]; P < .001; glomerulonephritis: HR, 0.21 [95% CI, 0.10-0.44]; P < .001; other conditions: HR, 0.33 [95% CI, 0.23-0.49]; P < .001). Adolescents had a lower risk for CV mortality than young adults for all causes of ESRD except glomerulonephritis (cystic, hereditary, and congenital conditions: HR, 0.45 [95% CI, 0.27-0.74]; glomerulonephritis: HR, 0.99 [95% CI, 0.76-1.11]; other: HR, 0.47 [95% CI, 0.40-0.57]). Higher risks for CV hospitalization and mortality were associated with lack of preemptive transplant compared with hemodialysis (hospital: HR, 14.24 [95% CI, 5.92-34.28]; mortality: HR, 13.64 [95% CI, 8.79-21.14]) and peritoneal dialysis [hospital: HR, 8.47 [95% CI, 3.50-20.53]; mortality: HR, 7.86 [95% CI, 4.96-12.45]). Nephrology care before ESRD was associated with lower risk for CV mortality (HR, 0.77 [95% CI, 0.70-0.85]). Cardiovascular disease accounted for nearly 40% of deaths in young adults with incident ESRD in this cohort. Identified risk factors may inform development of age-appropriate ESRD strategies to improve the CV health of this population.

Identifiants

pubmed: 30892557
pii: 2728081
doi: 10.1001/jamacardio.2019.0375
pmc: PMC6484951
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-362

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK007378
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK070869
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Am Soc Nephrol. 2014 Jun;25(6):1321-9
pubmed: 24652791
Am J Kidney Dis. 2018 May;71(5):648-656
pubmed: 29132947
J Pediatr. 2002 Aug;141(2):191-7
pubmed: 12183713
Am J Clin Nutr. 2004 Jul;80(1):193-8
pubmed: 15213048
Semin Dial. 2007 Nov-Dec;20(6):577-85
pubmed: 17991208
Am J Kidney Dis. 2012 Dec;60(6):1002-11
pubmed: 23022429
Natl Vital Stat Rep. 2016 Jun;65(4):1-122
pubmed: 27378572
N Engl J Med. 2004 Jun 24;350(26):2654-62
pubmed: 15215481
MMWR Recomm Rep. 2010 Sep 10;59(RR-9):1-15
pubmed: 20829749
J Am Soc Nephrol. 2017 May;28(5):1584-1591
pubmed: 28034898
Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9
pubmed: 9820470
Am J Transplant. 2011 Oct;11(10):2093-109
pubmed: 21883901
Stat Med. 1995 Mar 15-Apr 15;14(5-7):615-27
pubmed: 7792452
Am J Kidney Dis. 2017 Aug;70(2):281-289
pubmed: 28143671
Am J Kidney Dis. 2017 Mar;69(3 Suppl 1):A7-A8
pubmed: 28236831
Stat Med. 1997 Apr 30;16(8):901-10
pubmed: 9160487
Stat Methods Med Res. 2013 Dec;22(6):661-70
pubmed: 22072596
N Engl J Med. 2019 Jan 10;380(2):142-151
pubmed: 30586318
J Am Soc Nephrol. 2016 Feb;27(2):551-8
pubmed: 26054540
Nephrol Dial Transplant. 2005 Nov;20(11):2420-6
pubmed: 16115854
Int J Epidemiol. 2015 Feb;44(1):324-33
pubmed: 25501468
Clin Kidney J. 2015 Dec;8(6):772-80
pubmed: 26613038
Crit Care Med. 2016 Aug;44(8):1530-7
pubmed: 26985636
Am J Kidney Dis. 2015 Jul;66(1 Suppl 1):Svii, S1-305
pubmed: 26111994
Am J Kidney Dis. 2001 Nov;38(5):992-1000
pubmed: 11684552
Blood Purif. 2011;31(1-3):203-8
pubmed: 21228591
Kidney Int. 2016 Aug;90(2):389-395
pubmed: 27157696
Pediatr Nephrol. 2017 Dec;32(12):2319-2330
pubmed: 28762101
Pediatr Nephrol. 2005 Jul;20(7):849-53
pubmed: 15834618
J Am Soc Nephrol. 2019 Feb;30(2):201-215
pubmed: 30655312
Nephrol Dial Transplant. 2010 Apr;25(4):1025-32
pubmed: 20019018
Kidney Int. 2003 Mar;63(3):793-808
pubmed: 12631061

Auteurs

Zubin J Modi (ZJ)

Division of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor.
Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor.

Yee Lu (Y)

Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor.

Nan Ji (N)

Arbor Research Collaborative for Health, Ann Arbor, Michigan.

Alissa Kapke (A)

Arbor Research Collaborative for Health, Ann Arbor, Michigan.

David T Selewski (DT)

Division of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor.

Xue Dietrich (X)

Arbor Research Collaborative for Health, Ann Arbor, Michigan.

Kevin Abbott (K)

National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Kidney Urology and Epidemiology, Bethesda, Maryland.

Brahmajee K Nallamothu (BK)

Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor.
Michigan Integrated Center for Health Analytics & Medical Prediction, University of Michigan, Ann Arbor.

Douglas E Schaubel (DE)

Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor.
Kidney Epidemiology and Cost Center, School of Public Health, University of Michigan, Ann Arbor.

Rajiv Saran (R)

Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor.
Kidney Epidemiology and Cost Center, School of Public Health, University of Michigan, Ann Arbor.
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor.

Debbie S Gipson (DS)

Division of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH